Anti-aging as commerce is a steadily growing industry. It is estimated that by 2024, the anti-aging business market will be worth $271 billion.
Most people know that products that purport to halt or reverse aging don’t work or only provide minimal aesthetic improvement. However, that doesn’t stop them from seeking out ever more radical procedures.
In 2016, a company called Ambrosia was launched that uses the blood of the young in a transfusion process to slow aging. The FDA says there is no no evidence that the procedure works.
Numerous science experts and researchers, some of whom had their research used by Ambrosia to further its practices, warn the public that the company’s methods are dangerous.
Nevertheless, Ambrosia now offers the procedure in five American cities and may expand operations depending on demand.
Promises of youth
Ambrosia was launched by Jesse Karmazin. Karmazin is a Stanford Medical School graduate but is not licensed to act as a medical practitioner. Ambrosia offers its youth rejuvenating services via transfusion as an “off-label” medical treatment, meaning that it is an unapproved treatment procedure.
Ambrosia transfuses the blood of people aged 16 to 25 into its customers on the idea that the blood of the young will rejuvenate the internal organs of older people. The company charges $8,000 for one-liter blood transfusions and $12,000 for two-liter transfusions.
Ambrosia conducted clinical trials in 2017 but has yet to share its findings. The company’s product is based on Stanford University research and a 150-year procedure called parabiosis.
The procedure has never been proven to reverse ageing. The recent research conducted on it was to search for treatments for various medical conditions, not anti-aging cures.
The researchers whose work Ambrosia built upon have made public warnings that its anti-aging procedures may be life threatening. They can cause issues with immunity, mismatched transfused blood cells can attack the patient’s cells, and other problems.
The FDA released a public warning about Ambrosia’s procedures without naming the company. Ambrosia halted operations for a few weeks earlier this year but is now operating in San Francisco, California and Tampa, Florida.
The company claims to be operating in Los Angeles, Omaha, and Houston. Ambrosia has reportedly infused over 150 people, aged between 35 ad 92, with the blood of the young.
Small-cap winners galoreThe big stock market winners share one common attribute: Near the beginning of the ascent of their shares, the companies offer revolutionary products or services, are market leaders in their respective industries, or both. Some big stock market winners that possessed the attributes outlined above are Netflix (NFLX), which we recommended to investors in October 2002; Intuitive Surgical (ISRG), which we bought and recommended in July 2004; Baidu.com (BIDU), which we bought and recommended in August 2006; and MercadoLibre (MELI), which we recommended to investors in October 2010. Get up-to-date small-cap stock picks from David Frazier, editor of Small-Cap Profit Confidential.
Smarter cryptocurrency investmentsThe stock market crash of 2008 was the catalyst for his journey into alternatives. And interestingly, it was the impetus behind the creation of Bitcoin and the blockchain technology behind it. Keene Little wasn’t ready to risk his money yet but he was very curious, so he began charting Bitcoin’s technical patterns. What finally convinced him to dip a toe into digital currencies was seeing that they followed familiar price patterns that could be analyzed and successfully acted on. Now he shares those insights with subscribers to the Crypto Wealth Protocol.